ZNF312 Inhibitors
Chemical inhibitors of ZNF312 can modulate its function by targeting various signaling pathways that influence its role in transcriptional regulation. PD 98059 and U0126, both MEK inhibitors, can prevent the activation of the ERK pathway. This inhibition results in reduced phosphorylation of ERK, which is upstream of transcriptional events that ZNF312 may influence. By disrupting this signaling route, these inhibitors can decrease the ability of ZNF312 to regulate gene expression. Similarly, LY294002 and Wortmannin, as PI3K inhibitors, can impede the activation of AKT. The inhibition of AKT reduces the nuclear localization of transcription factors that ZNF312 may regulate. By preventing these transcription factors from functioning effectively in the nucleus, the inhibitors can attenuate the influence of ZNF312 on gene expression.
Other inhibitors such as SP600125 and SB203580 target MAPK pathways different from the ERK pathway. SP600125 inhibits JNK, while SB203580 targets p38 MAP kinase. These kinases are also implicated in the phosphorylation and activation of transcription factors. Inhibition of these kinases can lead to reduced activity of transcription factors that are potentially regulated by ZNF312, resulting in diminished gene regulatory functions of ZNF312. GF109203X, Ro-31-8220, and Go6983, which are inhibitors of PKC, can disrupt other signaling pathways that might intersect with ZNF312's regulatory mechanisms. By hindering PKC activity, these inhibitors can affect the phosphorylation status of various substrates that can interact with ZNF312, leading to a decrease in ZNF312's regulatory capacity. Lastly, H-89, an inhibitor of PKA, and Y-27632, an inhibitor of ROCK, can also alter signaling cascades and cytoskeletal dynamics, respectively. Such changes can influence the cellular localization and activity of transcriptional regulators associated with ZNF312, culminating in a decrease in its functional impact on gene expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). Since ZNF312 is a zinc finger protein that may be involved in transcriptional regulation, inhibiting ERK phosphorylation may result in reduced transcriptional activity of ZNF312-regulated genes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. PI3K inhibition can reduce the activation of AKT, which may be involved in the nuclear localization of transcription factors that could be regulated by ZNF312, leading to decreased function of ZNF312 in the nucleus. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can influence the activity of transcription factors and, consequently, gene expression. By inhibiting JNK, SP600125 might hinder the activity of transcription factors potentially co-regulated by ZNF312, thereby decreasing ZNF312's functional output. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can impair the phosphorylation of transcription factors that may be part of ZNF312's regulatory network, resulting in decreased ZNF312 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, like PD 98059, and it prevents the activation of ERK1/2. By blocking MEK, U0126 can decrease the transcriptional regulation capabilities of ZNF312 by impeding the signaling pathway it may influence. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, by inhibiting PI3K, it can prevent AKT activation and subsequent transcription factor activity modulation, potentially diminishing ZNF312's influence on gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR), which is a key regulator of cell growth and proliferation. By inhibiting mTOR, it might disrupt processes that are crucial for the expression of genes regulated by ZNF312, leading to reduced activity of ZNF312. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X is an inhibitor of protein kinase C (PKC). PKC inhibition could disrupt signaling pathways that intersect with ZNF312's regulatory functions, thus inhibiting ZNF312-mediated transcriptional activation. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro-31-8220 is a potent PKC inhibitor, like GF109203X. By inhibiting PKC, it can affect the phosphorylation status of substrates that may interact with ZNF312, potentially reducing ZNF312's ability to regulate gene expression. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a broad-spectrum PKC inhibitor. It can inhibit multiple PKC isoforms, which might be involved in pathways that regulate the activity of ZNF312, thus decreasing the regulatory function of ZNF312 in the cell. | ||||||